Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- February29 2004
- Volume 11
- Issue 4
On the Up & Up
Advertisement
(Barron's, 2004)
34.7%—Annual return for the average US stock mutual fund in 2003.
(Association of American Medical Colleges, 2004)
$109,457—Total educational debt of the average US medical school graduate in 2003.
Articles in this issue
about 18 years ago
Choose Wisely when Managing Your Debtsabout 18 years ago
Avoid the Problems with Switching Banksabout 18 years ago
Be a Thoughtful and Caring Grandparentabout 18 years ago
Teach Financial Skills to Your Childrenabout 18 years ago
Safeguard Yourself from Identity Theftabout 18 years ago
Happiness, Elusive, but Somewhere Out Thereabout 18 years ago
Fund Fundamentalsabout 18 years ago
Diversified Portfoliosabout 18 years ago
Doing Some Flipsabout 18 years ago
Offbeat Market IndicatorsAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5